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Abstract 
Neurofibromatosis type 2 (NF2) gene, a tumor suppressor gene located on chromosome 22q12.2, is 
frequently abnormal in mesothelioma. Recent studies have revealed the effectiveness of diagnostic 
assays for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. 
These include detection of homozygous deletion of the 9p21 locus by fluorescence in situ 
hybridization (FISH) (9p21 FISH), loss of expression of BAP1 as detected by 
immunohistochemistry, and loss of expression of methylthioadenosine phosphorylase (MTAP) as 
detected by immunohistochemistry. However, the application of FISH detection of NF2 gene 
deletion (NF2 FISH) in differentiation of malignant pleural mesothelioma from reactive mesothelial 
hyperplasia has not been fully evaluated. In this study, we investigated whether NF2 FISH, either 
alone or in a combination with other diagnostic assays (9p21 FISH, MTAP immunohistochemistry, 
and BAP1 immunohistochemistry), is effective for distinguishing malignant pleural mesothelioma 
from reactive mesothelial hyperplasia. This study cohort included malignant pleural mesothelioma 
(n = 47) and reactive mesothelial hyperplasia cases (n = 27) from a period between 2001 and 2017. 
We used FISH to examine deletion status of NF2 and 9p21 and immunohistochemistry to examine 
expression of MTAP and BAP1 in malignant pleural mesothelioma and in reactive mesothelial 
hyperplasia. Hemizygous NF2 loss (chromosome 22 monosomy or hemizygous deletion) was 
detected in 25 of 47 (53.2%) mesothelioma cases. None of the mesothelioma cases showed 
homozygous NF2 deletion. Hemizygous NF2 loss showed 53.2 % sensitivity and 100% specificity in 
differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia. A 
combination of NF2 FISH, 9p21 FISH, and BAP1 immunohistochemistry yielded greater sensitivity 
(100%) than that detected for either diagnostic assay alone (53.2 % for NF2 FISH, 78.7% for 9p21 
FISH, 70.2% for MTAP immunohistochemistry, or 57.4% for BAP1 immunohistochemistry). Thus, 
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NF2 FISH in combination with other diagnostic assays is effective for distinguishing malignant 
pleural mesothelioma from reactive mesothelial hyperplasia. 
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Malignant pleural mesothelioma is the most common primary neoplasm of the pleura.1 Its incidence 
is closely linked with exposure to asbestos fibers.1 The prognosis of malignant pleural mesothelioma 
is generally poor with a median survival period of 9.2 to 14 months.2,3 Although, histologic 
diagnosis of malignant pleural mesothelioma is not always straightforward,1 diagnosis at an early 
stage may lead to a better prognosis.4,5  
     Mesothelioma has frequent genetic alterations in Cyclin-dependent kinase inhibitor 2A 
(CDKN2A)/p16 found in the 9p21 locus (35–62%), BRCA1-associated protein 1 (BAP1) (21–63%), 
and neurofibromatosis type 2 (NF2) (14–50%).6,7 Recent studies have revealed the usefulness of 
assays detecting changes in the 9p21 locus and BAP1 expression for mesothelioma diagnosis – 
homozygous deletion of the 9p21 locus as detected by fluorescence in situ hybridization (FISH) 
(9p21 FISH)8–17 and expression loss of BAP1 as detected by immunohistochemistry.12,15–21 In 
addition, we have previously reported that immunohistochemical detection of methylthioadenosine 
phosphorylase (MTAP) is a reliable surrogate assay for 9p21 FISH.14,15,17,22–24 These aforementioned 
assays can provide a definitive diagnosis of mesothelioma and can facilitate differentiation of 
malignant mesothelial proliferations from benign proliferations with 100% specificity.1,15–17,23,25 
Although the sensitivity of either of these assays on their own is insufficient, the combined use of 
9p21 FISH (or MTAP immunohistochemistry) and BAP1 immunohistochemistry enhances the 
sensitivity.12,14–17,21,23,25 
     The NF2 is a tumor suppressor gene which is located on chromosome 22q12.2 and 
encodes moesin-ezrin-radixin-like protein (merlin).26 This protein modulates signal transduction 
pathways including Hippo pathways and mammalian target of rapamycin (mTOR) pathways, which 
regulate cell proliferation, growth, and apoptosis.26 Inactivation of the NF2 gene has been observed 
in certain benign and malignant tumors including neurofibromatosis type 2, sporadic schwannoma, 
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meningioma, and mesothelioma.26 
Genetic mutations in NF2 are frequently observed in mesothelioma.6,7,27 Singhi et al.28 
showed the prevalence of NF2 hemizygosity in 35% of peritoneal mesotheliomas cases using FISH. 
However, the application of NF2 FISH for differentiating malignant pleural mesothelioma from 
reactive mesothelial hyperplasia has not been established in pleural mesotheliomas. In this study, we 
investigated whether NF2 FISH, either alone or in a combination with other diagnostic assays, is 
effective for distinguishing malignant pleural mesothelioma from reactive mesothelial hyperplasia. 
Materials and Methods 
Case selection 
This study included malignant pleural mesothelioma and reactive mesothelial hyperplasia cases 
identified from the pleural lesion files of the Department of Pathology, Fukuoka University Hospital, 
which includes pleural diseases such as malignant pleural mesothelioma, reactive mesothelial 
hyperplasia, various pleuritis, metastatic carcinomas, and primary thoracic sarcomas, between the 
years of 2001 and 2017. Histological diagnosis and classification of mesothelioma were performed 
according to the 2015 World Health Organization guidelines.29 The mesothelial nature of each tumor 
was confirmed using immunohistochemistry assays. Calretinin, podoplanin (D2–40), and Wilms’ 
tumor-1 (WT-1) were used as positive mesothelial markers, while thyroid transcription factor-1 
(TTF-1), Ber-EP4, claudin-4, and carcinoembryonic antigen (CEA) were used as negative markers.  
Each mesothelioma case was classified into three histologic types (epithelioid, biphasic, 
or sarcomatoid). Classification of either epithelioid or sarcomatoid mesothelioma required at least 
90% of the tumor to be composed of this morphologic pattern.1,29 Biphasic mesothelioma 
classification required both components to represent at least 10% of the tumor.1,29 
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Anonymous use of redundant tissues is part of the standard treatment agreement with 
patients at our hospital, provided no objection is expressed. The Fukuoka University Hospital 
Institutional Review Board approved the study protocol (approval number: 11-7-11). 
FISH assay 
A representative tissue specimen from each case was selected for FISH analysis. The FISH studies 
were carried out on 4-μm-thick tissue sections as previously described.11,13,15,23 Sections were 
deparaffinized and rehydrated using descending alcohol dilutions, washed with 2x saline-sodium 
citrate (SSC), exposed to pretreatment solution at 80 °C for 30 minutes (PathVysion HER2 DNA 
probe kit; Vysis, Downers Grove, IL, USA), and digested with pepsin solution (Sigma-Aldrich, 
Tokyo, Japan) at 37 °C for 90 minutes. After refixation in 10% buffered formalin at room 
temperature (RT) for 10 minutes, the sections were treated with 2x SSC, dehydrated in ethanol, dried, 
and exposed to Vysis LSI p16/CEP 9 probe (Abbott Japan, Tokyo, Japan) and NF2/CEN 22q probe 
(Abnova, Walnut, CA, USA). Tissue sections were denatured at 80 °C for 10 minutes in the probe 
solution provided (Abbott Japan), followed by hybridization at 37 °C for 20 hours in ThermoBrite 
(Abbott Japan). Finally, the tissue sections were washed with 2x SSC containing 0.3% Tween 20 
(Sigma, St. Louis, MO, USA) at 72 °C for 2 minutes and then with 2x SSC containing 0.1% Tween 
20 at RT for 5 minutes. Nuclei were counterstained with 4’, 6-diamidino-2-phenylindole (DAPI) in 
Antifade reagent (Vector Laboratories, Burlingame, CA, USA). Analyses were performed using a 
fluorescence microscope (Axio Imager Z1; Carl Zeiss MicroImaging, Jena, Germany) and Isis 
analysis system (MetaSystems, Altlussheim, Germany) equipped with filter sets with single and 
dual-band exciters for spectrum green, spectrum orange, and DAPI (UV 360 nm). 
Lymphocytes in each preparation served as internal controls and showed two signals per 
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FISH probe. The use of internal controls helped to confirm that loss of FISH signals was not due to 
preanalytical factors such as fixation or processing. We evaluated the FISH signal patterns in at least 
100 mesothelial cells per sample. A cutoff value of 10% was set for homozygous deletion of 9p21 
FISH as described previously.11,14–16,30  
As for NF2 FISH, signal cutoff values for each deletion pattern [hemizygous deletion, 
chromosome 22 monosomy, homozygous deletion, and one fluorescein isothiocyanate (FITC) signal 
were established according to the mean frequency (%) + 3 standard deviations (SDs) for each of the 
patterns in the reactive mesothelial hyperplasia cases.11 We defined one Spectrum Red (SpR) and 
two Spectrum Green (SpG) signals (1SpR/2SpG) as hemizygous deletion, 1SpR/1SpG as 
chromosome 22 monosomy, 0SpR/2SpG as homozygous deletion, and 0SpR/1SpG as one FITC 
signal. In this study, hemizygous NF2 loss indicates hemizygous NF2 deletion (1SpR/2SpG) or 
chromosome 22 monosomy (1SpR/1SpG), as described previously.28 
Immunohistochemistry of MTAP and BAP1 
A representative tissue specimen from each case was selected for immunohistochemistry analysis. 
Immunostaining was performed on 4-μm-thick sections which were mounted on a glass microscope 
slide. After blocking the endogenous peroxidase activity using blocking reagent (included in the 
Dako Envision Kit, Dako, California, USA) for 5 minutes at RT, epitopes were retrieved using pH 
9.0 Tris-EDTA buffer for 40 minutes at 95 °C followed by incubation with mouse monoclonal 
antibody MTAP clone 2G4 (Abnova, Taipei, Taiwan; 1:100 dilution; RT 30 minutes) or mouse 
monoclonal anti-human BAP-1 clone C-4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:50 
dilution; RT 45 minutes). The sections were then washed and incubated with ChemMate EnVision 
kit (Dako). Immunoreacted cells were visualized using diaminobenzidine (Dako, California, USA) 
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followed by a hematoxylin counterstain. 
Non-mesothelial cells that were immunoreactive to BAP1 and MTAP (e.g., 
inflammatory cells including histiocytes and lymphocytes, fibroblasts, pneumocytes, and endothelial 
cells) served as internal positive controls in each staining protocol. BAP1 immunohistochemistry 
revealed staining in the nucleus, and BAP1 loss in tumor cells was defined as complete nuclear 
loss.14,15,23 Cytoplasmic staining was interpreted as a nonspecific reaction. MTAP 
immunohistochemistry revealed cytoplasmic as well as nuclear staining, and MTAP loss as detected 
by immunohistochemistry in tumor cells was defined as cytoplasmic staining at an intensity lower 
than the internal positive control.14,15,23,31 We set the cutoff value at 50% for MTAP 
immunohistochemistry and BAP1 immunohistochemistry, as described previously.14,15,19,23 
Statistical analysis 
Continuous data are shown as the group means (±SD), and categorical data are shown as a 
percentage of the group. Fisher’s exact test was used to compare categorical variables. The 
differences in the mean values of continuous data were assessed using Student’s t-test for unpaired 
data. We performed survival analysis using overall survival as the endpoint, beginning at the time of 
resection. The survival curves were plotted via the Kaplan-Meier method, and the differences 
between survival curves were analyzed using the log-rank test. A p-value of <0.05 was considered to 
indicate statistical significance. All statistical analyses were performed using R (version 3.2.2; R 
Foundation for Statistical Computing, Vienna, Austria.). 
 
Results 
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Clinicopathological characteristics 
Forty-seven cases with malignant pleural mesothelioma and 27 cases with reactive mesothelial 
hyperplasia were included in this study. Mesothelioma cases comprised 41 males and 6 females with 
a mean age of 67.3 years (range: 45–86 years) and included 32 epithelioid mesothelioma, 5 
sarcomatoid mesothelioma, and 10 biphasic mesothelioma cases. Reactive mesothelial hyperplasia 
cases included 26 males and 1 female with a mean age of 33.0 years (range: 18–78 years). 
NF2 and 9p21 FISH 
Mesothelial cells with a normal copy number for 9p21 or NF2 have two red signals (9p21 probe or 
NF2 probe) and two green signals (chromosome 9 or chromosome 22 centromeric probes). In 
mesothelioma, NF2 deletion as detected by FISH was characterized by hemizygous loss 
(hemizygous deletion: 1SpR/2SpG or chromosome 22 monosomy: 1SpR/1SpG). Mesothelioma cells 
with homozygous 9p21 deletion showed 0SpR/2SpG signal profile. Representative examples of NF2 
FISH and 9p21 FISH in reactive mesothelial hyperplasia and malignant pleural mesothelioma cases 
are shown in Fig. 1 and 2, respectively. 
Determination of the cutoff values for NF2 FISH 
The signal cutoff values (calculated as indicated in the Materials and Methods section) for NF2 
FISH were determined to be 18.2% for hemizygous deletion (1SpR/2SpG), 48.4% for chromosome 
22 monosomy (1SpR/1SpG), 5.5% for homozygous deletion (0SpR/2SpG), and 12.9% for one FITC 
signal (0SpR/1SpG) (Table 1). 
MTAP and BAP1 immunostaining  
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BAP1 immunohistochemistry shows staining in the nucleus. BAP1 loss in mesothelioma showed 
nuclear staining at an intensity lower than that in the internal positive controls. MTAP 
immunohistochemistry showed cytoplasmic staining as well as nuclear staining and MTAP loss in 
mesothelioma showed cytoplasmic staining at an intensity lower than that in the internal positive 
controls. BAP1 loss was detected in 27 of the 47 mesothelioma cases (57.4%), whereas none of the 
reactive mesothelial hyperplasia cases showed BAP1 loss. Meanwhile, MTAP loss was detected in 
33 of the 47 mesothelioma cases (70.2%), while none of the reactive mesothelial hyperplasia cases 
showed MTAP loss. Representative examples of MTAP and BAP1 immunostaining in mesothelioma 
cases are shown in Fig. 3. 
Deletion status of NF2 using FISH 
Hemizygous NF2 loss was detected in 25 of the 47 mesothelioma cases (53.2%; 4.3% for 
1SpR/2SpG and 48.9% for 1SpR/1SpG), while homozygous NF2 deletion was not detected in 
mesothelioma cases. Neither hemizygous loss nor homozygous deletion of NF2 was observed in 
reactive mesothelial hyperplasia cases. 
The correlation between hemizygous NF2 loss and other parameters in malignant 
pleural mesothelioma is summarized in Table 2. Hemizygous NF2 loss was not associated with age 
(p=0.39), gender (p=0.67), or histologic subtype (p=0.32), statistically. It is noteworthy that 
hemizygous NF2 loss was also not associated with homozygous 9p21 deletion (p=0.73), MTAP loss 
as detected by immunohistochemistry (p=0.52), or BAP1 loss as detected by immunohistochemistry 
(p=0.77), statistically. 
Sensitivity and specificity of detection assays for discriminating malignant pleural 
mesothelioma from reactive mesothelial hyperplasia 
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The results for each detection assay in the 47 mesothelioma cases are shown in Figure 4. The 
sensitivity and specificity of each detection assay for discriminating malignant pleural mesothelioma 
from reactive mesothelial hyperplasia are summarized in Table 3. None of the reactive mesothelial 
hyperplasia cases showed loss of expression of BAP1 or MTAP as detected by 
immunohistochemistry or deletion of NF2 or 9p21 as detected by FISH. Thus, each detection assay 
was characterized by a 100% specificity. Assay sensitivities were 53.2% for NF2 FISH, 78.7% for 
9p21 FISH, 70.2% for MTAP immunohistochemistry, and 57.4% for BAP1 immunohistochemistry. 
The assay sensitivity was increased to 93.6% for the combination of 9p21 FISH and BAP1 
immunohistochemistry and to 89.4% for the combination of MTAP immunohistochemistry and 
BAP1 immunohistochemistry. A triple combination of NF2 FISH, 9p21 FISH, and BAP1 
immunohistochemistry yielded greater sensitivity (100%) than that detected for either diagnostic 
assay alone or for the combination of either two of these assays.  
Survival analysis 
Overall survival curves for patients with malignant pleural mesothelioma are shown in Figure 5. As 
expected, there was a significant difference in overall survival based on the histologic type (p=0.001) 
(Fig. 5A). Similarly, 9p21 homozygous deletion detected by FISH and MTAP loss detected by 
immunohistochemistry were clearly associated with a shorter overall survival (p<0.001 and p<0.001, 
respectively) (Fig. 5B and C). However, BAP1 loss detected by immunohistochemistry or 
hemizygous NF2 loss detected by FISH were not associated with a shorter overall survival (Fig. 5D 
and E). 
 
Discussion 
12 
 
In this study, we revealed that NF2 loss as detected by FISH was characterized by hemizygous loss. 
Hemizygous NF2 loss was not associated with FISH detection of homozygous 9p21 deletion, 
immunohistochemical detection of MTAP loss, or immunohistochemical detection of BAP1 loss. 
Hemizygous NF2 loss showed 53.2% sensitivity and 100% specificity in differentiating malignant 
pleural mesothelioma from reactive mesothelial hyperplasia. In this cohort, NF2 FISH in a 
combination with diagnostic assays for 9p21 homozygous deletion (FISH) and BAP1 expression 
loss (immunohistochemistry), is effective for distinguishing malignant pleural mesothelioma from 
reactive mesothelial hyperplasia at 100% specificity and sensitivity. 
Karyotypic studies have previously shown that clonal abnormalities in chromosome 22 
are the most frequent site of chromosomal aberrations in mesothelioma (39.2–65.0%).32,33 A limited 
number of studies have investigated the frequency of NF2 deletion in mesothelioma using 
FISH.28,34,35 Vivero et al.34 reported that the frequency of NF2 deletion detected by FISH was 72.5% 
(37/51 cases) in malignant pleural mesothelioma (cutoff values: 4% for monosomy and 8% for 
hemizygous deletion). Takeda et al.35 reported that the frequency of chromosomal loss at 22q12 
detected by FISH was 38% in malignant pleural mesothelioma cases (cutoff values: not described). 
Singhi et al.28 showed that NF2 loss as detected by FISH was identified in 35% of peritoneal 
mesotheliomas (cutoff values: not described). The frequency of NF2 deletion detected by FISH is 
highly influenced by the cutoff value used for the analysis of FISH signal. Using procedure 
described in Materials and Methods section, the cutoff values calculated in our study were 48.4% for 
monosomy and 18.2% for hemizygous deletion. Applying these criteria, hemizygous NF2 loss 
detected by FISH could differentiate malignant pleural mesothelioma from reactive mesothelial 
hyperplasia with 53.2% sensitivity and 100% specificity. 
In the above-mentioned peritoneal mesothelioma study, NF2 loss as detected by FISH 
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was characterized by hemizygous loss (35%), and chromosome 22 monosomy (30%) was more 
frequent than hemizygous NF2 deletion (5%).28 In our study, the frequency of hemizygous NF2 loss 
in malignant pleural mesothelioma (53.2%) was higher than that in peritoneal mesothelioma. 
Meanwhile, similar to the peritoneal mesothelioma study, chromosome 22 monosomy (48.9%) was 
more frequent than hemizygous NF2 deletion (4.3%). In contrast to 9p21 FISH, homozygous NF2 
deletion was not detected in any of the mesothelioma cases in our study as well as in other previous 
reports.17,28 Thus, NF2 loss as detected by FISH appears to be characterized by hemizygous loss in 
mesothelioma with chromosome 22 monosomy being more frequent than hemizygous NF2 deletion. 
Clinically, 9p21 FISH and BAP1 immunohistochemistry have 100% specificity for 
differentiating malignant mesothelial proliferations from benign proliferations.1,14–17,23,25 Chiosea et 
al.9 first reported the usefulness of 9p21 FISH for detecting mesothelioma cells in tissue sections. 
For differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia, 9p21 
FISH shows a sensitivity of 45%–85% in epithelioid mesothelioma 8–12,14,17 and 67%–100% in 
sarcomatoid mesothelioma.21,23 The role of BAP1 in mesothelioma was first suggested in reports of 
BAP1 somatic mutations by Bott et al.27 and of germline mutations in BAP1 by Testa et al.36 For 
differentiation between malignant pleural mesothelioma from reactive mesothelial hyperplasia, 
BAP1 immunohistochemistry shows a sensitivity of 56%–81% in epithelioid mesothelioma 12,17,18 
and 0–63% in sarcomatoid mesothelioma.12,18,21,23 In addition, we have previously reported that 
MTAP immunohistochemistry is an acceptable surrogate assay for 9p21 FISH, a finding that was 
also supported by Berg et al.14,15,17,23 In our previous study, 65%–75% of the malignant pleural 
mesothelioma cases harboring 9p21 homozygous deletion (detected by FISH), demonstrated MTAP 
loss detected by immunohistochemistry.14,15,23 In addition, MTAP immunohistochemistry 
distinguished malignant mesothelial proliferations from benign proliferations with a specificity of 
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100% and a sensitivity of 45.1% in epithelioid mesothelioma and 80% in sarcomatoid 
mesothelioma.14,15,23  
In the current study, hemizygous NF2 loss as detected by FISH was not correlated with 
FISH detection of 9p21 homozygous deletion, immunohistochemical detection of MTAP loss, or 
immunohistochemical detection of BAP1 loss. Therefore, the combined use of NF2 FISH and these 
three diagnostic assays can enhance the sensitivity of malignant pleural mesothelioma differentiation 
from reactive mesothelial hyperplasia. Indeed, a triple combination of NF2 FISH, 9p21 FISH, and 
BAP1 immunohistochemistry yielded greater sensitivity (100%) than that detected for either 
diagnostic assay alone or either combination of two of these assays. 
Technical challenges and cost can limit FISH assays from widespread adoption. 
Unfortunately, immunohistochemistry assays for the NF2 gene have not shown efficacy in the 
differentiation of malignant pleural mesothelioma from reactive mesothelial hyperplasia, to date. In 
their study examining the usefulness of merlin immunohistochemistry for the differentiation of 
mesothelioma from a benign proliferation, Sheffield et al.37 concluded that merlin 
immunohistochemistry is unsuitable due to its low sensitivity (4%) and the discordance between 
NF2 genetic changes and immunohistochemical detection of merlin expression. Recent studies have 
identified alterations in the components of the Hippo signaling cascade in mesothelioma cells, 
including large tumor suppressor homolog 2 (LATS2) and their downstream effectors Yes-associated 
protein (YAP) and transcriptional coactivator with the PDZ-binding motif (TAZ) complex.38 37 The 
application of immunohistochemical detection of LATS and YAP/TAZ immunohistochemistry for 
the differentiation of mesothelioma from a benign proliferation was also investigated; however, these 
immunohistochemistry assays were also found to be unsuitable due to their low sensitivity or 
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specificity.37 Nevertheless, further investigation may be needed to fully elucidate whether 
immunohistochemical detection of NF2 has a role in mesothelioma diagnosis. 
In mesothelioma, functional inactivation of NF2/merlin is known to be associated 
with mesothelial oncogenesis, invasiveness, spreading, and migration.39,40 A recent study showed 
that low merlin expression as detected by immunohistochemistry is related to the poor prognosis of 
malignant pleural mesothelioma.41 In peritoneal mesothelioma, Singhi et al.28 showed that 
hemizygous NF2 deletion as detected by FISH was significantly associated with a poor prognosis. 
However, in our current study，there was no significant prognostic implications of hemizygous NF2 
loss in malignant pleural mesothelioma. Merlin is inactivated by not only genetic alteration but also 
by epigenetic events (e.g. phosphorylation).39 Thurneysen et al.39 revealed that merlin is rendered 
inactive upon phosphorylation in all malignant pleural mesothelioma cases wherein no NF2 
truncation could be detected. The lack of association between hemizygous NF2 loss and survival 
observed in our study might be because merlin is frequently inactivated even in mesothelioma cases 
harboring wild-type NF2 gene.  
Our study has a few limitations. First, this study is a single-center retrospective study, 
and the number of patients is relatively small due to the rarity of the disease. Validation studies are 
preferred to confirm these results. Second, several old samples were utilized in our study with some 
cases dating back to 2001. However, for FISH analysis, we obtained two red and green FISH signals 
in the internal control cells as described in the Materials & Methods section; this validated the 
reactivity of FISH analysis. Third, inactivation of NF2 gene in the remaining allele of chromosome 
22 showing hemizygous loss could not be examined. This is relevant in light of the fact that 
inactivation of NF2 gene occurs via a two-hit mechanism.40,42 However, previous studies have 
shown that more than half of mesothelioma cases harboring allelic loss of 22q also showed NF2 
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gene mutation in the remaining allele.43,44 More studies are warranted to confirm these findings. 
In conclusion, FISH assay shows that the most common molecular alteration of NF2 
in malignant pleural mesothelioma is hemizygous loss. NF2 FISH in a combination with other 
diagnostic assays was effective for distinguishing malignant pleural mesothelioma from reactive 
mesothelial hyperplasia. 
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Figure legend 
Figure 1.  
Hematoxylin-eosin staining and NF2 dual-color fluorescence in situ hybridization in reactive 
mesothelial hyperplasia (A and B) and malignant pleural mesothelioma (C and D). A and B, 
mesothelial cells with a normal copy number showing 2 spectrum red and 2 spectrum green signals. 
C and D, mesothelioma cells with hemizygous NF2 loss showing 1 spectrum red and 1 spectrum 
green signals (pattern of chromosome 22 monosomy).  
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Figure 2. 
Hematoxylin-eosin staining and 9p21 dual-color fluorescence in situ hybridization in reactive 
mesothelial hyperplasia (A and B) and malignant pleural mesothelioma (C and D). A and B, 
mesothelial cells with a normal copy number showing 2 spectrum red and 2 spectrum green signals. 
C and D, mesothelioma cells with homozygous 9p21 deletion showing the pattern of 0 spectrum red 
and 2 spectrum green signals. 
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Figure 3. 
Representative examples of MTAP and BAP1 immunohistochemistry in malignant pleural 
mesothelioma. Non-mesothelial cells that were reactive to BAP1 and MTAP served as internal 
positive controls in each staining protocol. Preserved BAP1 immunohistochemistry (nuclear 
staining) (A), loss of BAP1 immunohistochemistry (B), preserved MTAP immunohistochemistry 
(cytoplasmic staining) (C), and loss of MTAP immunohistochemistry (D) are shown. 
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Figure 4. 
The results of each detection assay in the 47 cases of malignant pleural mesothelioma. Green 
represent retained expression as determined by immunohistochemistry or fluorescence in situ 
hybridization (FISH); red represents loss or deleted expression as detected by immunohistochemistry 
or FISH; black represents undetermined expression as detected by immunohistochemistry. Note: For 
9p21 FISH, deleted indicates homozygous deletion; for NF2 FISH, deleted indicates hemizygous 
loss.  
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Figure 5.  
Overall survival curves for patients with malignant pleural mesothelioma. The effect of histologic 
type (A), the status of 9p21 FISH (B), MTAP immunohistochemistry (C), NF2 FISH (D), and BAP1 
immunohistochemistry (E) on overall survival curves is shown.  
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Table 1. The cutoff values for NF2 FISH. 
NF2 FISH signal Cutoff values (mean + 3SD in RMH) (%) 
Hemizygous loss  
Hemizygous deletion (1SpR/2SpG) 18.2 
Chromosome 22 monosomy (1SpR/1SpG) 48.4 
Homozygous deletion (0SpR/2SpG) 5.5 
One FITC signal (0SpR/1SpG) 12.9 
FISH: fluorescence in situ hybridization; SD: standard deviation; RMH: reactive mesothelial 
hyperplasia; SpR: spectrum red; SpG: Spectrum Green; FITC: fluorescein isothiocyanate 
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Table 2. The correlation between hemizygous NF2 loss and other parameters in malignant pleural 
mesothelioma. 
Factor Group Hemizygous loss 
(n=25) 
wild type 
(n=22) 
p-value 
Age ≥70 9 (36.0) 11 (50.0) 0.39 
 <70 16 (64.0) 11 (50.0)  
Gender Female 4 (16.0) 2 (9.1) 0.67 
 Male 21 (84.0) 20 (90.9)  
Histologic subtype Epithelioid 18 (72.0) 14 (63.6) 0.32 
 Sarcomatoid 1 (4.0) 4 (18.2)  
 Biphasic 6 (24.0) 4 (18.2)  
9p21 FISH Homozygous deletion 19 (76.0) 18 (81.8) 0.73 
 Wild type 6 (24.0) 4 (18.2)  
MTAP IHC Loss 16 (68.0) 17 (77.3) 0.52 
 Retained 8 (32.0) 5 (22.7)  
BAP1 IHC Loss 15 (60.0) 12 (54.5) 0.77 
 Retained 10 (40.0) 10 (45.5)  
FISH: fluorescence in situ hybridization; IHC: immunohistochemistry 
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Table 3. Sensitivity and specificity of each detection assay for discriminating malignant pleural 
mesothelioma from reactive mesothelial hyperplasia.  
  
MPM (n=47) 
 
RMH (n=27) 
Sensitivit
y (%) 
Specificity 
(%) 
  
Loss or 
deleted† 
Retained 
 
Loss or 
deleted† 
Retained 
NF2 FISH  25 22  0 27 53.2 100 
9p21 FISH  37 10  0 27 78.7 100 
MTAP IHC＊  33 13  0 27 70.2 100 
BAP1 IHC  27 20  0 27 57.4 100 
BAP1 IHC/9p21 FISH  44 3  0 27 93.6 100 
BAP1/MTAP IHC  42 5  0 27 89.4 100 
NF2 FISH/ BAP1 
IHC/9p21 FISH 
 47 0  0 27 100 100 
NF2 FISH/ BAP1 
IHC/MTAP IHC 
 46 1  0 27 97.9 100 
MPM: malignant pleural mesothelioma; RMH: reactive mesothelial hyperplasia; FISH: fluorescence 
in situ hybridization; IHC: immunohistochemistry 
＊One case was excluded from sensitivity and specificity calculation for MTAP IHC due to data 
interpretation issues. 
† For 9p21 FISH, deleted indicates homozygous deletion; for NF2 FISH, deleted indicates 
hemizygous loss. 
 
 
